• About
  • Subscribe
  • Advertise
  • Contact
Sunday, May 18, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

EssilorLuxottica: OPSM and Sunglass Hut stand out in AU$11.9B Q1 2025

by Staff Writer
May 6, 2025
in Company updates & acquisitions, Local, News, Ophthalmic insights
Reading Time: 3 mins read
A A
The OPSM optical network was highlighted for “growing with higher conversion and price-mix”. Images: EssilorLuxottica.

The OPSM optical network was highlighted for “growing with higher conversion and price-mix”. Images: EssilorLuxottica.

Share on FacebookShare on Twitter

OPSM and Sunglass Hut have been singled out as strong contributors towards a successful, €6.8 billion (AU$11.9 b) first quarter (Q1) of 2025 for EssilorLuxottica.

The group posted its financials for the first three months of the year on 23 April 2025, with the Asia-Pacific region showing double-digit growth – up 10.4% on the same period in 2024, at constant exchange rates.

Asia-Pacific, which counts Australia and New Zealand, generated €852 million in revenue (AU$1.5 b) – €84 million (AU$147 m) more than Q1 2024.

In a presentation to investors, the 375-store OPSM optical network was highlighted for “growing with higher conversion and price-mix”.

Also, Sunglass Hut Australia had a positive result, helped by the introduction of Ray-Ban Meta smart glasses.

Other APAC highlights included a “sound performance in China, supported by myopia solutions and pick-up in frames”, myopia solutions up by around 30% in China led by Stellest and Nikon DOT, and Japan continuing double-digit same-store sales trajectory.

Overall, EssilorLuxottica’s Q1 2025 revenue reached €6.8 billion (AU11.9 b), representing a year-on-year increase of 7.3% at constant exchange rates compared to Q1 2024 (+8.1% at current exchange rates).

The company reported “sound growth” across both its professional solutions (products and equipment supplied to independents) and direct-to-consumer (optical practices and shopfronts) channels, with comparable-store sales up 8%.

“In the first quarter, we successfully maintained strong momentum, with all regions and businesses contributing to steady growth (in constant currency terms) – each playing an integral role in advancing our journey in the wearables and med-tech space,” said Mr Francesco Milleri, chairman and CEO, and Mr Paul du Saillant, deputy CEO.

“From the new six-year clinical data confirming long-term efficacy of Stellest in slowing myopia progression to the transformative Nuance Audio launch marking an entirely new category in the US, Italy and France, we are making significant strides toward our strategic goals.”

The executives said EssilorLuxottica’s brands were “showing the power of relevance like never before”.

This included Ray-Ban Meta’s “extraordinary trajectory”, Oakley celebrating its 50th year of being “the world’s favourite sport performance brand”, and Oliver Peoples extending its partnership with legend Roger Federer.

“At the heart of this momentum are our 200,000 dedicated colleagues, whose commitment and passion fuel our continued success,” Milleri and du Saillant said.

“Their growing involvement as shareholders stands a powerful testament to their trust in our company and the values that define us. In a time of uncertainty, we advance with purpose, ambition and confidence in the future we are building together.”

More reading

Momentum continues behind EssilorLuxottica ANZ business

New six-year data for Essilor Stellest lenses in slowing myopia progression

This Australian optometrist is prescribing plano defocus lenses to prevent myopia

 

Related Posts

Dr Lourens van Zyl recently switched to Blink eye drops in his clinic. Images: B+L.

Bausch + Lomb’s blinking success

by Staff Writer
May 17, 2025

Every second counts in Dr Lourens van Zyl’s busy Perth clinic, motivating him to switch to a new lubricating eye...

The cost of intravitreal eye injections to manage macular degeneration can discourage many older Australians from continuing treatment. Image: Rose Makin/stock.adobe.com.

Special Report: Intravitreal injections and bulk billing – good for business

by Rob Mitchell
May 16, 2025

Frequent intravitreal injections are vital to help many older Australians keep their eyesight, but the costs can be prohibitive. Insight...

A scene from the movie My Eyes, featuring optometrist Tsu Shan Chambers (right). Image: FanForce Films.

My Eyes film starring Australian optometrist set to open in theatres

by Staff Writer
May 16, 2025

A film highlighting the remarkable journey of a Australian mother determined to save her daughter’s eyesight, and starring a practising...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited